FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

The Food and Drug Administration on Friday warned oncologists and clinical trial investigators of early signs from two trials that some bladder cancer patients treated first with either Merck & Co.'s Keytruda or Roche's Tecentriq alone were dying sooner than those given platinum-based chemotherapy.